Chemotactic activity of serum obtained from patients with idiopathic dilated cardiomyopathy

H H Sigusch1, M H Lehmann, D Reinhardt

  • 1University of Jena, Department of Internal Medicine, Division of Cardiology, 07740 Jena, Germany. Holger.Sigusch@med.uni-jena.de

Die Pharmazie
|September 13, 2006
PubMed

Insights

Serum from idiopathic dilated cardiomyopathy patients exhibits high chemotactic activity, linked to elevated monocyte chemoattractant protein-1 (MCP-1) levels. This finding offers insights into heart failure pathogenesis.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • Elevated alpha- and beta-chemokines are implicated in heart failure.
  • Understanding chemokine roles in idiopathic dilated cardiomyopathy (IDCM) is crucial.

Purpose of the Study:

  • To investigate the relationship between serum chemotactic activity and circulating chemokine levels in IDCM patients.
  • To compare these levels with coronary artery disease (CAD) patients and healthy controls.

Main Methods:

  • Quantified serum chemokine levels (MCP-1, MIP1-alpha, RANTES, IL-8, TNF-alpha) in IDCM, CAD (normal and depressed left ventricular function), and control groups.
  • Assessed serum chemotactic activity using an in vitro chemotaxis assay.

Main Results:

  • IDCM patients' sera displayed significantly higher chemotactic activity (5475 +/- 681 cells) compared to controls (1850 +/- 215 cells), CAD-1 (3325 +/- 275 cells), and CAD-2 (2800 +/- 275 cells).
  • Elevated circulating monocyte chemoattractant protein-1 (MCP-1) levels were significantly associated with the heightened chemotactic activity observed in IDCM sera.

Conclusions:

  • Serum from IDCM patients demonstrates potent chemotactic activity.
  • Elevated MCP-1 levels are strongly correlated with this increased chemotactic effect in IDCM, suggesting a key role in the disease.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...